SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX)
BCRX 7.385-3.1%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (224)10/27/2008 9:24:09 PM
From: IRWIN JAMES FRANKEL  Read Replies (2) of 269
 
>>There were no statistically significant differences in any of the efficacy endpoints between the three treatment arms.

That could mean either:

- peramivir is not better than Tamiflu; or

- peramivir, if better, the degree of advantage could not be established due to the small trial size relative to the drug effect.

Do I have that right?

I did not see anything in the release that even teased me to think that peramivir is better. Did I miss it?

Thanks

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News